Key Details
Price
$1.66Last Dividend
$277.34 KAnnual ROE
-884.87%Beta
0.81Events Calendar
Next earnings date:
Mar 26, 2025Recent quarterly earnings:
Nov 14, 2024Recent annual earnings:
Mar 26, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
Apr 23, 2008Next split:
N/ARecent split:
Jan 29, 2025Analyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Events
Dividend per share
Dividend yield
Other
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced the closing of its previously announced public offering of an aggregate of 1,666,666 shares of its common stock (or common stock equivalents in lieu thereof), Series A warrants to purchase up to 1,666,66.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced the pricing of a public offering of an aggregate of 1,666,666 shares of its common stock (or common stock equivalents in lieu thereof), Series A warrants to purchase up to 1,666,666 shares of common stoc.
Enveric Biosciences (NASDAQ: ENVB ) stock is heading higher on Tuesday alongside heavy pre-market trading of the biotechnology company's shares. This comes with more than 13 million shares of ENVB stock changing hands as of this writing.
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB). The update note includes information on the Enveric Bioscience's management commentary, recent developments, outlook, and risks.
Enveric Biosciences, Inc. (ENVB) closed at $0.93 on the most recent trading day, showing a decrease of 0.46% from its previous closing price.
Enveric Biosciences, Inc. (ENVB) ended the latest trading day at $0.90, down 0.56% from the day before.
Enveric Biosciences (ENVB) could see an increase in its stock price due to increasing optimism about its earnings potential, as indicated by its upgrade to a Zacks Rank #1 (Strong Buy).
On April 12, 2024, ZUO, INTZ, SIGA, ENVB, and NTRS were included in the Zacks Rank #1 (Strong Buy) List.
Biotech investors know that small companies can make massive moves on big headlines, and we're seeing such a move in Enveric Biosciences (NASDAQ: ENVB ) today. Shares of ENVB stock are up more than 120% in early afternoon trading today after the company put forward a press release highlighting plans to license three classes of its compounds.
Enveric Biosciences, Inc. (ENVB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
FAQ
- What is the ticker symbol for Enveric Biosciences?
- Does Enveric Biosciences pay dividends?
- What sector is Enveric Biosciences in?
- What industry is Enveric Biosciences in?
- What country is Enveric Biosciences based in?
- When did Enveric Biosciences go public?
- Is Enveric Biosciences in the S&P 500?
- Is Enveric Biosciences in the NASDAQ 100?
- Is Enveric Biosciences in the Dow Jones?
- When was Enveric Biosciences's last earnings report?
- When does Enveric Biosciences report earnings?
- Should I buy Enveric Biosciences stock now?